$1.16 Billion is the total value of MPM BioImpact LLC's 29 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TCRR | Buy | TCR2 Therapeutics, Inc. | $208,528,000 | +204.4% | 6,741,964 | +100.0% | 18.01% | +9.1% |
| RPTX | Buy | Repare Therapeutics, Inc. | $163,840,000 | +122.9% | 4,776,674 | +100.0% | 14.15% | -20.1% |
| ITOS | Buy | iTeos Therapeutics, Inc. | $159,330,000 | +174.2% | 4,711,114 | +100.0% | 13.76% | -1.7% |
| ONCR | New | Oncorus, Inc. | $153,698,000 | – | 4,754,062 | +100.0% | 13.27% | – |
| HARP | Buy | Harpoon Therapeutics, Inc. | $129,506,000 | +95.5% | 7,796,844 | +100.0% | 11.18% | -29.9% |
| TPTX | Buy | Turning Point Therapeutics, Inc. | $75,226,000 | +179.0% | 617,372 | +100.0% | 6.50% | 0.0% |
| EPZM | Buy | Epizyme, Inc. | $56,322,000 | +65.4% | 5,186,271 | +81.7% | 4.86% | -40.7% |
| Buy | MEI Pharma, Inc. | $53,528,000 | +69.2% | 20,275,718 | +100.0% | 4.62% | -39.3% | |
| GTHX | Buy | G1 Therapeutics, Inc. | $51,228,000 | +211.5% | 2,847,588 | +100.0% | 4.42% | +11.7% |
| ADCT | Buy | ADC Therapeutics, Inc. | $34,548,000 | +94.1% | 1,079,296 | +100.0% | 2.98% | -30.4% |
| YMAB | Buy | YmAbs Therapeutics, Inc. | $33,398,000 | +157.9% | 674,582 | +100.0% | 2.88% | -7.6% |
| MRUS | Buy | Merus N.V. | $24,572,000 | +192.1% | 1,401,758 | +100.0% | 2.12% | +4.7% |
| NTLA | New | Intellia Therapeutics, Inc. | $6,972,000 | – | 128,162 | +100.0% | 0.60% | – |
| AVRO | New | AVROBIO, Inc. | $5,078,000 | – | 364,285 | +100.0% | 0.44% | – |
| BDTX | New | Black Diamond Therapeutcs, Inc. | $1,398,000 | – | 43,615 | +100.0% | 0.12% | – |
| AUTL | Buy | Autolus Therapeutics Limited | $710,000 | +53.3% | 79,480 | +100.0% | 0.06% | -45.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
| Repare Therapeutics, Inc. | 14 | Q3 2023 | 19.7% |
| TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
| iTeos Therapeutics, Inc. | 13 | Q3 2023 | 15.7% |
| G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
| Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
| Cullinan Oncology, Inc. | 11 | Q3 2023 | 41.4% |
| Epizyme, Inc. | 11 | Q2 2022 | 22.1% |
| Oncorus, Inc. | 11 | Q2 2023 | 13.3% |
| Intellia Therapeutics, Inc. | 10 | Q3 2023 | 5.5% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| SC 13D/A | 2023-08-01 |
| SC 13D | 2023-06-12 |
| 4 | 2023-06-05 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-11 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.